Innate Pharma SA Net Income Loss

Quick Answer

Innate Pharma SA reported Net Income Loss of -$58.10 million for the year ending 2022.

  • Innate Pharma SA showed a decrease of -10.0% in Net Income Loss from 2021 to 2022.
  • This data is from Innate Pharma SA's annual report (Form 10-K), filed with the SEC on April 6, 2023.
  • XBRL data for this metric is available from 2018 to 2022 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 5 years of available data (2018 to 2022), Innate Pharma SA's Net Income Loss has declined by 2,005.6%.
  • Historical annual values: Fiscal year 2022: -$58.10 million | Fiscal year 2021: -$52.81 million | Fiscal year 2020: -$63.98 million | Fiscal year 2019: -$20.76 million | Fiscal year 2018: $3.05 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: